# EDIT — slm-full-cpu

## Metadata

ticker: EDIT
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: c069eefc08204e64484c429dc4bb7aae865ae25cd8bdaa5961e547ee82555294
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 659, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 136.039, "latency_s_total": 136.039, "parse_failure": 0, "prompt_tokens": 2385, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 604, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 130.207, "latency_s_total": 130.207, "parse_failure": 0, "prompt_tokens": 2374, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 129, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 45.029, "latency_s_total": 45.029, "parse_failure": 0, "prompt_tokens": 615, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 145, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 53.359, "latency_s_total": 53.359, "parse_failure": 0, "prompt_tokens": 609, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 207, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 103.675, "latency_s_total": 103.675, "parse_failure": 0, "prompt_tokens": 676, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 145, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 53.36, "latency_s_total": 53.36, "parse_failure": 0, "prompt_tokens": 739, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 930, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 111.314, "latency_s_total": 111.314, "parse_failure": 0, "prompt_tokens": 1630, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.62,
  "currency": "USD",
  "market_cap": 402379680.0,
  "forward_pe": -3.4788148,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin": -1.57322,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filings for ticker EDIT, here are the key takeaways regarding the company's financial position, operational status, and risks:

**Financial Position and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stands at $1.6 billion.
*   **Need for Additional Funding:** The company requires substantial additional capital to fund ongoing operations. If unable to raise capital when needed or on attractive terms, the company may be forced to delay, reduce, or eliminate research, product development, or commercialization efforts.
*   **Cash Runway:** Existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027.
*   **Limited External Sources:** The only significant committed potential external sources of funds are the right to contingent payments under collaboration agreements with BMS and retained portions of contingent upfront payments under a license agreement with Vertex.
*   **Dilution Risks:** Raising additional capital through public or private equity offerings may cause dilution to stockholders, restrict operations, or require the relinquishment of rights to technologies or product candidates.

**Operational Status and Development**
*   **Preclinical Stage:** The company’s most advanced research programs are currently in the preclinical testing stages. It is expected to be many years, if ever, before a product candidate is ready for commercialization.
*   **Primary Candidate:** A significant portion of expenses and efforts is devoted to the preclinical and clinical development of EDIT-401.
*   **Revenue Timeline:** Commercial revenues are not expected for years, if at all. The company does not expect to generate substantial product revenues until it can successfully identify candidates, complete trials, obtain marketing approval, and commercialize medicines.

**Risk Factors**
*   **Profitability Uncertainty:** The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability. Failure to become profitable could decrease company value and impair the ability to raise capital or continue operations.
*   **Expanding Expenses:** Expenses are expected to increase significantly due to costs associated with drug discovery, preclinical and clinical trials, regulatory reviews, intellectual property maintenance, and potential future commercialization activities (sales, marketing, manufacturing).
*   **Regulatory and Economic Risks:** Expenses could exceed expectations if regulatory authorities (such as the FDA or EMA) require additional studies. Additionally, unfavorable national or global economic conditions, political unrest, or financial market disruptions could adversely affect the business, demand for products, and the ability to raise capital.
*   **Commercialization Challenges:** Even if product candidates are approved, the company may not achieve commercial success and will require significant additional funding to launch and commercialize products.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

**Financial Position and Need for Additional Capital**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion.
*   **Uncertainty of Profitability:** The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability. Even if profitability is achieved, it may not be sustainable on a quarterly or annual basis.
*   **Need for Funding:** Substantial additional funding is required to support ongoing activities, including preclinical studies and clinical trials for EDIT-401, as well as other research programs. If capital cannot be raised when needed, the company may be forced to delay, reduce, or eliminate research and development programs or commercialization efforts.
*   **Limited Committed Funds:** As of December 31, 2025, existing cash and cash equivalents are expected to fund operations only into the third quarter of 2027. The only significant committed potential external sources of funds are rights to contingent payments under collaboration agreements with Bristol Myers Squibb Company (BMS) and retained portions of payments under a license agreement with Vertex Pharmaceuticals.
*   **Dilution and Restrictions:** Raising additional capital through equity offerings, debt financings, or other arrangements may cause dilution to stockholders, restrict operations, or require the relinquishment of rights to technologies or product candidates.

**Operational and Development Risks**
*   **Preclinical Stage:** The most advanced research programs are currently only in the preclinical testing stages. It may be many years, if ever, before a product candidate is ready for commercialization.
*   **High Costs and Uncertainty:** Identifying product candidates and conducting preclinical and clinical trials is time-consuming, expensive, and uncertain. Expenses may increase beyond expectations if regulatory authorities require additional studies.
*   **Commercialization Challenges:** Even if marketing approval is obtained, the company must successfully manufacture, market, and sell medicines. Significant commercialization expenses are expected if sales, marketing, and distribution are not handled by a collaborator.

**External and Economic Risks**
*   **Economic and Political Conditions:** Unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or making it difficult to raise capital on acceptable terms.
*   **Regulatory Risks:** The costs, timing, and outcomes of regulatory reviews by the FDA, EMA, or other authorities are uncertain factors that impact capital requirements and development timelines.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine, Inc. (EDIT) currently trades at $2.62 with a market capitalization of approximately $402.4 million. The company reported revenue of $47.0 million but faces significant profitability challenges, evidenced by a net loss of $73.9 million and a negative profit margin of -157.3%. Consequently, the forward P/E ratio is negative at -3.48, reflecting ongoing operational losses rather than earnings generation. This financial profile indicates a high-risk investment profile typical of early-stage biotechnology firms reliant on future pipeline developments for value realization.

### Recent Developments

Editas Medicine, Inc. (EDIT) continues to face significant financial headwinds, evidenced by a negative profit margin of -157.32% and a net loss of $73.95 million, underscoring the company's reliance on external capital to sustain operations. The recent filing of the 2026 Annual Report on Form 10-K highlights persistent risks related to its financial position and the necessity for additional funding to navigate ongoing losses. With the stock trading near its 52-week low of $1.66 at $2.62, investors should remain cautious as the company works to mitigate execution risks and achieve sustainable revenue growth.

### SEC Filing Highlights
Editas Medicine reported net losses of $160.1 million for the year ended December 31, 2025, bringing its accumulated deficit to $1.6 billion as it remains in the preclinical development stage. Existing cash and cash equivalents are projected to fund operations through the third quarter of 2027, after which the company will require substantial additional capital to sustain its pipeline. Primary financial resources are limited to contingent payments from collaboration agreements with BMS and Vertex, as commercial revenues are not expected for several years. Consequently, the company faces significant dilution risks and operational uncertainty if it cannot secure funding on attractive terms to support ongoing research and development.

### Risk Factors

*   **Substantial Financial Losses and Capital Requirements:** The company has incurred significant operating losses and holds a large accumulated deficit, with existing cash expected to fund operations only through Q3 2027. Failure to secure additional funding may force the delay or termination of R&D programs, while raising capital could result in significant shareholder dilution.
*   **Early-Stage Development and Commercialization Uncertainty:** The most advanced programs remain in preclinical stages, meaning it may be many years before any product reaches commercialization. The path to regulatory approval is highly uncertain, costly, and time-consuming, with no guarantee that product candidates will succeed in trials or achieve market acceptance.
*   **External Economic and Regulatory Headwinds:** Unfavorable global economic conditions, political unrest, or financial crises could disrupt supply chains and hinder capital raising efforts. Additionally, regulatory reviews by the FDA and other authorities carry inherent uncertainties regarding timing, costs, and outcomes that could adversely impact development timelines and capital requirements.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine, Inc. (EDIT) is a gene-editing company currently navigating the high-risk, preclinical development phase, characterized by a substantial accumulated deficit of $1.6 billion and reliance on external capital to sustain operations. The stock is notable for its proximity to the 52-week low of $1.66 and the imminent cash runway expiration in Q3 2027, which necessitates immediate strategic capital raising or partnership execution. The single most important near-term variable is the company’s ability to secure additional funding on attractive terms without excessive shareholder dilution before its existing cash reserves are depleted.

### Outlook
The directional outlook for Editas Medicine is cautiously neutral to negative, driven primarily by the binary nature of its near-term liquidity needs and the extended timeline to commercialization. Key variables to monitor include the execution of collaboration agreements with partners like BMS and Vertex, as well as the company’s success in raising capital before the Q3 2027 cash runway expiration. A strengthening of the investment thesis would require evidence of successful capital raising without severe dilution or positive preclinical data milestones that attract strategic interest; conversely, the view would weaken significantly if the company faces delays in funding or if regulatory hurdles extend the preclinical timeline further, increasing the risk of program termination or insolvency.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "substantial accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state "As of December 31, 2025, the accumulated deficit stands at $1.6 billion," and the Pre-written SEC Filing Highlights section repeats this figure.

---

CLAIM: "proximity to the 52-week low of $1.66"
LABEL: SUPPORTED
REASON: The stock data confirms the 52-week low is $1.66 and the current price is $2.62; the claim that the stock is near its 52-week low is arithmetically verifiable (2.62 is 57.8% above the low of 1.66, while the 52-week high is 4.537, placing the current price in the lower portion of the range), and the exact figure $1.66 matches the source data exactly.

---

CLAIM: "imminent cash runway expiration in Q3 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly state "existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027," which is also repeated in the Pre-written SEC Filing Highlights and Risk Factors sections.

---

**OUTLOOK**

---

CLAIM: "execution of collaboration agreements with partners like BMS and Vertex"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly name Bristol Myers Squibb (BMS) and Vertex Pharmaceuticals as the two collaboration/license agreement partners providing contingent external funding sources.

---

CLAIM: "the Q3 2027 cash runway expiration"
LABEL: SUPPORTED
REASON: Same source as above — the RAG SEC Highlights and Pre-written Risk Factors section both state cash is expected to fund operations "into the third quarter of 2027."

---

**SUMMARY OF FINDINGS**

All five auditable quantitative or forward-looking claims in the Executive Summary and Outlook sections are **SUPPORTED** by the source data. No figures were found to be unsupported or mere inferences. Notably, the brief contains relatively few hard numbers (no price targets, no specific ratios beyond what was in the pre-written sections, no percentages in these two sections), which limits the audit surface but also means no fabricated figures were introduced.
